Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03425006|
Recruitment Status : Terminated (Administrative reasons)
First Posted : February 7, 2018
Last Update Posted : May 27, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Non Small Cell Lung Cancer||Drug: Itacitinib Biological: Pembrolizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1|
|Actual Study Start Date :||June 18, 2018|
|Actual Primary Completion Date :||June 17, 2021|
|Actual Study Completion Date :||October 11, 2021|
|Experimental: Itacitinib and Pembrolizumab||
a JAK 1 selective small molecule inhibitor
Other Name: INCB039110
a highly selective humanized monoclonal antibody (mAb)
- Response Rate at 12 weeks according to RECIST 1.1 for the combination of pembrolizumab and itacitinib among patients with previously untreated, PD-L1 positive metastatic NSCLC. [ Time Frame: 12 weeks ]Responses will be compared subject's baseline assessment and historical controls using pembrolizumab monotherapy.
- Evaluate toxicities (CTCAE v5.0 scoring) of pembrolizumab and itacitinib in patients with previously untreated, PD-L1 positive metastatic NSCLC [ Time Frame: 16 weeks ]
- Median progression free survival (PFS) for subjects treated with pembrolizumab and itacitinib. [ Time Frame: 12 weeks ]
- Duration of response (DOR) for subjects treated with pembrolizumab and itacitinib. [ Time Frame: 12 weeks ]
- Overall survival (OS) for subjects treated with pembrolizumab and itacitinib. [ Time Frame: 16 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 1. Stage IV or metastatic non-small cell lung cancer (NSCLC)
- 2. Provide written informed consent for the trial.
- 3. Patients ≥ 18 years of age
- 4. Tumor PD-L1≥ 50% as assessed by the PD-L1 IHC 22C3 pharmDx assay (Dako North America).
- 5. Subject must have adequate tumor burden at a safely accessible site for biopsy. NOTE: If sites chosen for biopsy were previously irradiated, there must be evidence of tumor growth/viable tumor as assessed by the investigator.
- 6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- 7. ECOG performance status 0 or 1
- 8. Adequate Organ Function Laboratory Values: Absolute neutrophil count (ANC) ≥1,250/mcL; Platelets ≥100,000/mcL; Hemoglobin ≥9 g/dL or ≥5.6 mmol/L; Serum creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥50 mL/min for subject with creatinine levels > 1.5 X institutional ULN; Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases
- 9. Subjects of reproductive potential must agree to use acceptable birth control methods.
- 1. Sensitizing mutations in Epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) or ROS1 proto-oncogene receptor tyrosine kinase (ROS1) translocations
- 2. Currently participating in or has participated in a study of an investigational agent or anticipated use of an investigational device within 4 weeks of the first dose of study treatment.
- 3. Untreated symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.
- 4. Received prior systemic cytotoxic chemotherapy, biologic therapy, targeted therapy or immunotherapy for incurable (metastatic) NSCLC.
- 5. Diagnosis of immunodeficiencywithin 7 days prior to eligibility confirmation by the physician-investigator.
- 6. Prior monoclonal antibodies used for the treatment of NSCLC within 4 weeks prior to eligibility confirmation by the physician-investigator, or individuals who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- 7. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-invasive bladder tumors, or in situ cervical cancer
- 8. 8. Active autoimmune disease requiring systemic immunosuppressive treatment within the past 3 months prior to eligibility confirmation by the physician-investigator. Subjects that require intermittent use of steroid-containing bronchodilators or local steroid injections or topical steroid medications are not excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome are not excluded from the study.
- 9. Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
- 10. Active infection requiring systemic therapy with IV antibiotics
- 11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- 12. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- 13. Pregnant or breastfeeding women
- 14. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).
- 15. Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- 16. Known active Hepatitis B (e.g., HBsAg positive or HBV DNA detectable) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- 17. Anticipated receipt of any live vaccine within 30 days prior to the first dose of trial treatment.
Note: For the purposes of determining eligibility above, enrollment is defined as the date of subject consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03425006
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Corey Langer, MD||University of Pennsylvania|
Documents provided by University of Pennsylvania:
|Responsible Party:||University of Pennsylvania|
|Other Study ID Numbers:||
UPCC# 09517; IRB# 828910
|First Posted:||February 7, 2018 Key Record Dates|
|Last Update Posted:||May 27, 2022|
|Last Verified:||May 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Antineoplastic Agents, Immunological